Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Adma Biologics (ADMA) over the last 13 years, with Q3 2025 value amounting to -$14.4 million.

  • Adma Biologics' Cash from Investing Activities fell 120856.1% to -$14.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$24.4 million, marking a year-over-year decrease of 23690.54%. This contributed to the annual value of -$8.6 million for FY2024, which is 7215.42% down from last year.
  • Adma Biologics' Cash from Investing Activities amounted to -$14.4 million in Q3 2025, which was down 120856.1% from -$2.5 million recorded in Q2 2025.
  • In the past 5 years, Adma Biologics' Cash from Investing Activities ranged from a high of -$757000.0 in Q3 2023 and a low of -$14.4 million during Q3 2025
  • In the last 5 years, Adma Biologics' Cash from Investing Activities had a median value of -$2.8 million in 2024 and averaged -$3.3 million.
  • As far as peak fluctuations go, Adma Biologics' Cash from Investing Activities soared by 7786.85% in 2023, and later plummeted by 120856.1% in 2025.
  • Over the past 5 years, Adma Biologics' Cash from Investing Activities (Quarter) stood at -$3.7 million in 2021, then decreased by 1.98% to -$3.7 million in 2022, then soared by 62.46% to -$1.4 million in 2023, then crashed by 95.45% to -$2.8 million in 2024, then plummeted by 422.47% to -$14.4 million in 2025.
  • Its Cash from Investing Activities was -$14.4 million in Q3 2025, compared to -$2.5 million in Q2 2025 and -$4.7 million in Q1 2025.